Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, Beck IA, Yuthavisuthi P, Prommas S, Puthanakit T, Achalapong J, Chotivanich N, Rasri W, Cressey TR, Maupin R, Mirochnick M, Jourdain G; IMPAACT P1032 Protocol Team.

Clin Infect Dis. 2012 Jan 15;54(2):285-93. doi: 10.1093/cid/cir798. Epub 2011 Dec 5.

2.

Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.

McMahon DK, Zheng L, Hitti J, Chan ES, Halvas EK, Hong F, Kabanda J, Taulo F, Kumarasamy N, Bonhomme J, Wallis CL, Klingman KL, Hughes MD, Mellors JW.

Clin Infect Dis. 2013 Apr;56(7):1044-51. doi: 10.1093/cid/cis1219. Epub 2013 Jan 8.

3.

A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.

Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.

J Med Virol. 2015 Oct;87(10):1662-7. doi: 10.1002/jmv.24220. Epub 2015 May 4.

4.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
5.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
6.

Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.

Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators.

AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.

7.

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.

McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, Hall DB, Robinson P, Mayers D, Martinson NA.

PLoS Med. 2009 Oct;6(10):e1000172. doi: 10.1371/journal.pmed.1000172. Epub 2009 Oct 27.

8.

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team.

Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.

9.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
10.

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.

Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, Njiri F, John-Stewart GC.

Antivir Ther. 2008;13(6):799-807.

11.

Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.

Lidström J, Li Q, Hoover DR, Kafulafula G, Mofenson LM, Fowler MG, Thigpen MC, Kumwenda N, Taha TE, Eshleman SH.

AIDS. 2010 Jan 28;24(3):381-6. doi: 10.1097/QAD.0b013e3283352ef1.

12.

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.

Kesho Bora Study Group, de Vincenzi I.

Lancet Infect Dis. 2011 Mar;11(3):171-80. doi: 10.1016/S1473-3099(10)70288-7. Epub 2011 Jan 13. Erratum in: Lancet Infect Dis. 2011 Mar;11(3):159. Read, Jennifer S [corrected to Read, Jennifer].

PMID:
21237718
13.

Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.

Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, Broadhead RL.

JAMA. 2004 Jul 14;292(2):202-9.

PMID:
15249569
14.

Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.

Farr SL, Nelson JA, Ng'ombe TJ, Kourtis AP, Chasela C, Johnson JA, Kashuba AD, Tegha GL, Wiener J, Eron JJ, Banda HN, Mpaso M, Lipscomb J, Matiki C, Fiscus SA, Jamieson DJ, van der Horst C; BAN Study Team.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):515-23. Erratum in: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e53.

15.

Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.

Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, Mengistu Y, Omer SB, Isehak A, Kumbi S, Adamu R, Lulseged S, Ashworth R, Hassen E, Ruff A; Ethiopian Swen Study Team.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):823-9. doi: 10.1089/AID.2010.0346. Epub 2011 Feb 25.

16.

Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.

Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino E, Oyoo-Okoth E.

BMC Res Notes. 2014 Jan 21;7:52. doi: 10.1186/1756-0500-7-52. Retraction in: BMC Res Notes. 2014;7:868.

17.

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group.

N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.

18.

In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.

Church JD, Mwatha A, Bagenda D, Omer SB, Donnell D, Musoke P, Nakabiito C, Eure C, Bakaki P, Matovu F, Thigpen MC, Guay LA, McConnell M, Fowler MG, Jackson JB, Eshleman SH.

AIDS Res Hum Retroviruses. 2009 Jul;25(7):673-7. doi: 10.1089/aid.2009.0003.

19.

Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.

Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, McIntosh K, Thaineua V; Perinatal HIV Prevention Trial (Thailand) Investigators.

N Engl J Med. 2004 Jul 15;351(3):217-28. Epub 2004 Jul 9.

20.

Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.

Micek MA, Blanco AJ, Carlsson J, Beck IA, Dross S, Matunha L, Seidel K, Montoya P, Gantt S, Matediana E, Jamisse L, Gloyd S, Frenkel LM.

J Infect Dis. 2012 Jun 15;205(12):1811-5. doi: 10.1093/infdis/jis282. Epub 2012 Apr 5.

Supplemental Content

Support Center